* Valeant Canada, a subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX), announced its acquisition of the Canadian rights for Altace® (ramipril) and Altace HCT® (ramipril and hydrochlorothiazide), two angiotensin-converting enzyme (ACE) inhibitors approved by Health Canada and indicated for hypertension, from Sanofi Canada (NYSE: SNY). Valeant Canada will commercialize and manufacture Altace®/Altace HCT® locally at its Laval, Quebec facility. In doing so, Valeant will secure high quality production within Canadian standards and highly specialized Canadian jobs in its Quebec facility for years to come.
“In the treatment of patients deemed at high-risk of cardiovascular events, ramipril is an excellent
